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Background: Although lobectomy is considered the standard surgical treatment for the majority of patients with
non-small-cell lung cancer (NSCLC), the operation project for patients with stage IA NSCLC (T1a, tumor diameter
≤2 cm) remains controversial. Sublobectomy is appropriate only in certain patients as many doctors consider it to
be overtreatment. We evaluated the five-year overall survival rate of sublobectomy and lobectomy for stage IA
NSCLC (T1a, tumor diameter ≤2 cm) through a meta-analysis.
Methods: The five-year overall survival rate (OS) of stage IA (T1a) NSCLC after sublobectomy (including wedge re-
section and segmentectomy) and lobectomy were compared. We also compared the OS of stage IA (T1a) NSCLC
after segmentectomy and lobectomy. The log (hazard ratio, ln (HR)) and its standard error (SE) were used as the
outcome measure for data combining.
Results: There were 12 eligible studies published between 1994 and 2013 in which the total number of
participants was 18,720. When compared to lobectomy, there was a statistically significant difference of
sublobectomy on OS of stage IA (T1a) NSCLC patients (HR 1.38; 95% confidence interval (95% CI), 1.19 to 1.61; P
<0.0001). For the comparison between segmentectomy and lobectomy, there was also a statistically significant
difference of segmentectomy alone on OS of stage IA (T1a) NSCLC patients (HR 1.48; 95% CI: 1.27 to 1.73; P
<0.00001)
Conclusions: We have concluded that in stage IA (T1a) patients sublobectomy, including segmentectomy and
wedge resection, causes a lower survival rate than lobectomy.
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With the wide use of high-resolution computed tomog-
raphy (CT) and low-dose helical CT in lung cancer
screening, an increasing number of non-small-cell lung
cancers (NSCLCs) are diagnosed at the early T1 stage.
Considering the relatively good prognosis of T1 stage
NSCLC, many surgeons began to question the necessity
of a total lobectomy in the management of patients with
such small lesions [1-3]. As an alternative, sublobect-
omy, including wedge resection and segmentectomy,* Correspondence: pumchlsq@163.com
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unless otherwise stated.reduces the length of surgery, thus resulting in fewer
complications and shorter hospitalization time [4,5].
This procedure is only acceptable in cases with a tumor
size of less than 2 cm, according to the recommendation
from the National Comprehensive Cancer Network
(NCCN) Clinical Practice Guideline in Oncology for
NSCLC, version 2.2013, however the outcome of sublo-
bectomy is still controversial.
In 1995, the Lung Cancer Study Group (LCSG) com-
pared the outcomes of sublobar with lobar resection in a
randomized trial and demonstrated that patients with
sublobar resection had a lower survival rate [6]. The
same results have been published in some non-
randomized trials [7], which examine a comparison be-
tween wedge resection alone and lobectomy. However,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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section was not inferior to lobectomy regarding progno-
sis in patients with small and peripheral NSCLC [8]. The
results from the LCSG have been further challenged by
several retrospective studies, which have suggested that
limited resection might be equally effective in the treat-
ment of stage IA (T1a) patients with a tumor size of less
than 2 cm compared with lobectomy, particularly among
elderly patients [9-12].
To compare the outcome of sublobectomy and lobec-
tomy, Nakamura et al. conducted a meta-analysis of
published studies between 1970 and 2004 in 2005 [10].
The analysis indicated that the outcome of limited resec-
tion was comparable to lobectomy in patients with stage
I lung cancer. Since then, several large clinical trial re-
sults have been published. In 2012, Fan et al. conducted
another meta-analysis of published studies between 1990
and 2010 which indicated that for stage I patients, sublo-
bectomy causes a lower survival rate than lobectomy,
while for stage IA (T1a) patients, sublobectomy pro-
duces a similar survival rate to lobectomy [13]. Taking
all these into consideration, we felt it necessary to re-
evaluate the efficacy of sublobectomy in patients with
stage IA (T1a) NSCLC (tumor diameter ≤2 cm). We
therefore collected the updated data from published
studies between 1994 and 2013 and evaluated the effect-
iveness of sublobectomy compared to lobectomy for
stage IA (T1a) NSCLC (tumor diameter ≤2 cm) through
a meta-analysis of these studies.
Methods
Identification of studies
We searched PubMed using the strategy of (limited re-
section [Title/Abstract] OR (sublobar resection [Title/
Abstract]) OR (segmentectomy [Title/Abstract]) OR
(wedge resection [Title/Abstract]) AND (lung [Title/Ab-
stract] OR pulmonary [Title/Abstract]) AND (cancer
[Title/Abstract]) OR (carcinoma [Title/Abstract]) AND
(lobectomy [Title/Abstract]). We also searched Embase
by the strategy of ‘limited resection’: ab OR ‘sublobar re-
section’: ab OR segmentectomy: ab OR ‘wedge resec-
tion’: ab AND (lung: ab OR pulmonary: ab) AND
(cancer: ab OR carcinoma: ab) AND lobectomy: ab. The
citations of all retrieved articles were checked to identify
any other potentially relevant publications. The studies
in the search results were selected based on the inclu-
sion and exclusion criteria. The inclusion criteria were:
(i) outcomes of interest include overall survival rate (OS)
(ii) articles were peer-reviewed, published, and original
articles (iii) information was described in the article on
how the hazard ratio (HR) and standard error (SE) can
be calculated (iv) study subjects had to be limited to
clinical stage IA (T1a) patients, (v) patients were divided
into lobectomy and sublobectomy, (vi) if the enrolledpatients were from the same institutions and in the same
period, only the most recently published data would be
enrolled into the study. The exclusion criteria were: (i)
letters to editor, case reports, reviews, and non-English
articles (ii) patients were divided into segmentectomy
and wedge resection. In recent studies, the definition of
sublobectomy includes the wedge resection and segmen-
tectomy. Some of the studies analyzed the survival of pa-
tients after wedge resection or anatomic segmentectomy
separately, whereas some studies studied only the sur-
vival after sublobectomy. We enrolled studies in which
we could collect survival data after sublobectomy versus
lobectomy to further analyze the outcomes of these
results.
Statistical analysis
The log (hazard ratio, ln (HR)) and its standard error
(SE) were used as the outcome measure for data com-
bination [14,15]. The SE was obtained as:
ln(upper 95% CI) - ln(lower 95% CI)/3:92
The ln (HR) and its SE were calculated from the re-
ported data directly by HR and its 95% CI, or indirectly
by reading and extracting from the Kaplan-Meier sur-
vival curve [5,9,12,16-24]. The heterogeneity of included
studies was detected using the Cochran test. The publi-
cation bias was analyzed by Egger’s methods [25]. The
evidence of asymmetry was based on P <1. Kaplan-
Meier curves were read by Origin version 9 www.origi-
nlab.com. The data combining the test of heterogeneity
was conducted and analyzed using Review Manager Ver-
sion 5.1 http://www.cochrane.org/.
Results
The total number of studies obtained from the searches
were 1342 from PubMed and Embase. According to the
inclusion and exclusion criteria, there were 12 eligible
studies published between 1994 and 2013 [5,9,12,16-24].
All of these studies were retrospective studies. The char-
acteristics of all the included clinical trials are listed in
Table 1. The size of the cohorts varied from 72 to 5626,
with a total number of 18720 patients. In the analysis,
the sublobectomy group was the experimental group
and the lobectomy group was chosen as the reference.
There were a total of 12 studies involved in the analysis
that compared the impact of sublobectomy and lobec-
tomy on OS of Stage IA (T1a) NSCLC patients. The
combined HR of OS was 1.38 (95% CI, 1.19 to 1.61; P
<0.0001). The sublobectomy group was inferior to pa-
tients treated with lobectomy. The Cochran tests for het-
erogeneity showed that tau2 = 0.03; chi2 = 30.57 df =13
(P = 0.004); I2 = 57%, which suggested significant incon-
sistency; and so we choose to use the random method
instead random effects models (Figure 1). There was no
significant publication bias detected at the section of
Table 1 General characteristics of the enrolled studies
Study Stage Tumor size Comparison Outcome Sample size Sublobectomy Lobectomy
Koike et al. [5] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 233 74 159
Okada et al. [9] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 567 305 262
Whitson et al. [21] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 5626 291 5335
Wolf et al. [18] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 238 154 84
Kates et al. [24] Ia ≤1 cm sublobectomy vs lobectomy 5-year survival 2064 688 1376
Okada et al. [23] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 209 70 139
Okami et al. [22] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 764 146 618
Warren and Faber [12] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 72 38 34
Wisnivesky et al. [20] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 1165 196 969
Wisnivesky et al. [19] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 249 47 202
Yendamuri et al. (1987-1997) [17] Ia ≤2 cm sublobectomy vs lobectomy 5-year survival 1961 469 1492
Yendamuri et al. (1998-2004) [17] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 2691 150 2541
Yendamuri et al. (2005-2008) [17] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 2761 162 2599
Zhong et al. [16] Ia ≤2 cm segmentectomy vs lobectomy 5-year survival 120 39 81
The sublobectomy group did not distinguish between segmentectomy and wedge resection. In the study of Yendamuri et al. in 2013 [17], three groups of data in
different time periods were compared.
Liu et al. World Journal of Surgical Oncology 2014, 12:138 Page 3 of 6
http://www.wjso.com/content/12/1/138analysis (Figure 2). Taking the age into consideration, we
reasoned that the prognosis might be different in time
periods. To minimize this deviation we excluded all data
from before 2000 and made a future comparison. As a
result, there were only three studies involved, and unfor-
tunately, the outcome showed no statistical significance
(HR 1.38; 95% CI, 0.95 to 2.00; P = 0.09) (Figure 3). In
order to avoid the interaction between wedge resection
and segmentectomy, we also made a further comparison
between the segmentectomy group alone and the lobec-
tomy group (Figure 4). The combined HR of OS was
1.48 (95% CI, 1.27 to 1.73; P <0.00001). The result is
similar to that of the sublobectomy group. The Cochran
tests for heterogeneity showed that tau2 = 0.00; chi2 =
3.97 df =6 (P =0.68); I2 = 0%.Figure 1 Forest plot of HR for OS impact of operative approach (subl
combined HR displayed in this figure when compared with sublobectomy
stage IA patients with tumors no larger than 2 cm, (HR 1.38; 95% CI, 1.19 to
freedom; HR, hazard ratio, OS, overall survivalNSCLC,non-small cell lung canDiscussion
There are three original prospective randomized clinical
trials about the comparison between sublobectomy and
lobectomy. The earliest one is written by Ginsberg and
Rubinstein in 1995 [6] and was excluded because the
group division did not conform to our study. The other
two trials were launched by The National Cancer Insti-
tute (NCI) (CALGB 140503) in 2008 [13] and The Japan
Clinical Oncology Group with the West Japan Oncology
Group (JCOG0802/WJOG4607L) in 2009 [26]; both
comparing the survival of lobectomy and sublobectomy
for small peripheral non-small-cell lung cancer (≤2 cm).
Neither study has finished to date.
Before these studies publish their final results and con-
clusions, we used meta-analysis to combine currentobectomy versus lobectomy) of stage IA NSCLC patients. The
suggested that there was a significant benefit of lobectomy on OS of
1.61; P <0.0001) [5,9,12,16-24]. CI, confidence interval; df, degree of
cer; SE, standard error
Figure 2 Funnel plot of this analysis. The crossed two lines in the figure represent the 95% CI. This figure presents the impact of operative
approach (sublobectomy versus lobectomy) on OS of stage IA NSCLC patients with a tumor size of 2 cm or less.
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were drawn from the retrospective studies. We found
significant discrepancies among these studies for sample
size, distribution of histological types, gender ratio, rea-
sons for sublobectomy, and details of the operation.
These differences might contribute to inter-study het-
erogeneity, therefore, the random model in RevMan was
used for significant heterogeneities detection [27]. When
considering the possible existence of publication bias
among the enrolled studies, a test for publication bias
was performed and no significant publication bias was
detected after proper application of the above test.
The proper extent of pulmonary resection should
achieve complete eradication of the malignancy and re-
duce the damage as much as possible. The operation
project for patients with stage IA (T1a) NSCLC (tumor
diameter ≤2 cm) remains controversial and has been
under debate for several years.
We analyzed the impact of sublobectomy and lobec-
tomy on the OS of NSCLC patients with stage IA (T1a)
(tumors ≤2 cm). We found that the combined HR of OS
was 1.38 (95% CI, 1.19 to 1.61; P <0.0001). TheFigure 3 Forest plot of HR for OS impact of operative approach
(sublobectomy versus lobectomy) of stage IA NSCLC patients
with data after 2000. The combined HR displayed in this figure
suggested there was no statistical significance between
sublobectomy and lobectomy on OS (HR 1.38; 95% CI, 0.95 to 2.00;
P = 0.09). CI, confidence interval; df, degree of freedom; HR, hazard
ratio; OS, overall survival [16-18].sublobectomy group was inferior to patients treated with
the lobectomy. The segmentectomy group alone was
similar to confirmed (HR 1.48, 95% CI, 1.27 to 1.73; P
<0.00001). However, with recent data (data after 2000),
we did not get the same results in the comparison be-
tween sublobectomy and lobectomy groups; there was
no statistical significance (HR 1.38; 95% CI, 0.95 to 2.00;
P = 0.09). Since there were only three studies in this
comparison, we could not draw a definite conclusion,
however, there could be a correlation between good
prognosis and sublobectomy.
There are some limitations of this study:. (i) We could
not collect and analyze data about the chemotherapy
and radiotherapy information which might affect the
survival of some patients. (ii) We consider the clinical
stage more significant than the pathological one in
choosing a surgical method, however, most of the retro-
spective studies did not describe clearly whether the
stage was clinical or pathological; (iii) We think that the
comparison in patients who can tolerate the lobectomy
should be more powerful, however, most studies did not
separate the lobectomy tolerance group and non-
lobectomy tolerance group; (iv) Most studies did not
take systematic or sampling lymphadenectomy into con-
sideration, which could have an influence on the five-
year survival rate; (v) Studies on the field of comparison
between sublobectomy and lobectomy for stage IA (T1a)
NSCLC have not taken the appearance on CT (pure
solid, pure ground grass opacity (GGO), and part solid +
GGO.) into consideration, which is quite important to
the prognosis; and (vi) Retrospective studies could have
some bias due to reasons which have been mentioned
before.
Conclusions
The current meta-analysis disclosed that sublobectomy
(including wedge resection and segmentectomy) causes
lower OS in stage IA (T1a) NSCLC patients. We suggest
that lobectomy is the best optimal choice, which is in
line with the recommendation from National Compre-
hensive Cancer Network (NCCN) Clinical Practice
Guideline in Oncology for NSCLC version 2.2013.
Figure 4 Forest plot of HR for OS impact of operative approach (segmentectomy versus lobectomy) of stage IA NSCLC patients. The
combined HR displayed in this figure, compared with segmentectomy, suggest that there was a significant benefit of lobectomy on OS of stage
IA patients with tumors no larger than 2 cm (HR 1.48; 95% CI, 1.27 to 1.73; P <0.00001)]. CI, confidence interval; df, degree of freedom; HR, hazard
ratio; OS, overall survival [5,9,12,16,17,21].
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data from retrospective studies, the results of the meta-
analysis should be interpreted with caution and the data
of studies previously mentioned should be supplemented
with a further analysis in the coming future.
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